Cardiex Successfully Raises $6.5 Million Through Entitlement Offer

Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter CardieX ( (AU:CDX) ) has shared an announcement. Cardiex Limited announced the successful results of its fully underwritten, non-renounceable pro-rata entitlement offer, raising approximately $4.1 million. Together with a prior institutional placement, the company has secured a total of $6.5 million in funds. The entitlement offer, which was well-supported by shareholders, saw a take-up of approximately 50.3%, with the remaining shares allocated to underwriters. The funds will support Cardiex’s operations and potentially strengthen its position in the medical technology industry. More about CardieX Cardiex is a company focused on advancing medical technology in vascular health, offering products such as medical and home health devices and digital solutions for hypertension, cardiovascular disease, and other vascular health disorders. Their products are based on their market-leading SphygmoCor® vascular biomarker technology, and the company is listed on the Australian Stock Exchange (ASX:CDX). Average Trading Volume: 297,697 Technical Sentiment Signal: Sell Current Market Cap: A$22M For an in-depth examination of CDX stock, go to TipRanks’ Overview page. Trending Articles:All Eyes on Micron Stock Ahead of Earnings — Here’s What Stifel Expects ‘Don’t Ignore the Elephant in the Room,’ Says Investor About Intel Stock ‘Position Yourself for What’s Next,’ Says Investor About Nvidia StockDisclaimer & DisclosureLooking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.Report an Issue